Table 1.
Serial number | Name of the drug | Mode of action | Mode of administration | Adverse effects | References |
---|---|---|---|---|---|
1 | Pentavalent antimonials | Inhibition of glycolysis and β-oxidation of fatty acids of parasite | Intralesional for CL Parenteral |
Abdominal pain, erythema, nausea, toxicity (hepatic, pancreas, renal, muscular, and skeletal cardiothrombocytopenia or leukopenia) | [2, 60, 61] |
| |||||
2 | Amphotericin B | Binding to parasite's membrane sterols and changing its permeability selective to K+ and Mg2+ | Liposomal formulations Deoxycholate formulations |
Fever, nausea, hypokalemia, anorexia, leukopenia, kidney failure, and heart problems | [2, 59–61] |
| |||||
3 | Pentamidine | Interferes with DNA synthesis and modifies the morphology of kinetoplast | Parenteral Intramuscular administration |
Pain, nausea, vomiting, dizziness, myalgia, hypertension, headache, hypoglycemia, and transient hyperglycemia | [1, 2, 60, 61] |
| |||||
4 | Miltefosine | Associated with phospholipid biosynthesis and alkyl-lipid metabolism in Leishmania | Oral for VL | Nausea, vomiting, diarrhea, and raised creatinine | [1, 2, 59, 60] |
| |||||
5 | Paromomycin | Inhibition of protein biosynthesis in sensitive organism | Topical for CL Parenteral for VL |
Erythema, pain, oedema, and ototoxicity (damage to internal ear) | [1, 2, 60] |